Gene Expression Profiling Can Influence Melanoma Management

Clinical Oncology News | October 5, 2016 | Ajai Raj

A gene expression profiling test that classifies cutaneous melanoma (CM) patients into high- or low-risk categories for metastasis has been found to influence clinical management of CM patients, according to a team of investigators at multiple institutions in the United States.

Publishing in Current Medical Research and Opinion (2016;32[9]:1599-1604, PMID: 27210115), the investigators wrote that “the vast majority” of clinical changes implemented after the receipt of results from DecisionDx-Melanoma (Castle Biosciences), a 31-gene expression profiling test for CM, “were reflective of the low or high recurrence risk associated with the patient’s molecular classification.”

Read the full story here.

Know Your Risk

DecisionDx-Melanoma

A new genomic test is designed to predict if your cancer is at high risk of spreading, based on your tumor’s biology. Watch Video
Talk to Your Doctor
Decide with your doctor if DecisionDx-Melanoma is right for you. Download PDF
Gene Test Validation